跳至主要内容
临床试验/NL-OMON25346
NL-OMON25346招募中不适用

Assessment of contralateral cervical metastases using sentinel lymph node biopsy in patients with lateralized oral carcinoma and ipsilateral cervical metastasis: a pilot study

niversity Medical Center Utrecht0 个研究点目标入组 27 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
27

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • 1.The patient has provided written informed consent authorization before participating in the study.
  • 2.The patient has a diagnosis of primary lateralized oral squamous cell carcinoma, that does not involve the midline and is anatomically located in: mucosal lip, buccal mucosa, lower alveolar ridge, upper alveolar ridge, retromolar gingiva (retromolar trigone), floor-of-the-mouth, hard palate or oral (mobile) tongue.
  • 3.Clinical nodal staging of the positive ipsilateral neck (N1-N3) has been confirmed by ul-trasound, MRI and/or fine needle aspiration cytology within 30 days of the SLN procedure.
  • 4.Clinical nodal staging of the negative contralateral neck (N0) has been confirmed by neg-ative results from ultrasound, MRI and/or fine needle aspiration cytology within 30 days of the SLN procedure.
  • 5.The patient is a candidate for surgical tumor resection and ipsilateral neck dissection.
  • 6.Patients with prior malignancy in the head and neck area are allowed, provided the patient meets both of the following criteria:
  • Underwent potentially curative therapy for all prior head and neck malignancies and is deemed low risk for recurrence; and
  • No head and neck malignancy for the past five years (except effectively treated basal cell or squamous cell skin cancer) and no evidence of recurrence.
  • 7.The patient is =18 years of age at the time of consent.
  • 8.The patient has an ECOG status of Grade 0-2 (Appendix 4: Performance Status Criteria).

排除标准

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • 1.The patient has a diagnosis of squamous cell carcinoma of the head and neck in the fol-lowing anatomical areas: non-mobile base of the tongue, oropharynx, nasopharynx, hy-popharynx, and larynx.
  • 2.The patient is incapacitated.
  • 3.The patient has had a previous allergic reaction after administration of a radionuclide tracer.
  • 4.The patient has had other nuclear imaging studies, conducted within 10 days (240 hours) of injection.
  • 5.The patient has a history of neck dissection, or gross injury to the neck that would pre-clude reasonable surgical dissection for this trial, or radiotherapy to the neck.
  • 6.The patient is actively receiving systemic cytotoxic chemotherapy.
  • 7.The patient is on immunosuppressive, anti-monocyte, or immunomodulatory therapy.

研究者

相似试验